Brawn Biotech Limited reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported sales was INR 25.28 million compared to INR 147.82 million a year ago. Revenue was INR 25.28 million compared to INR 147.83 million a year ago. Net loss was INR 15.67 million compared to net income of INR 1.82 million a year ago. Basic loss per share from continuing operations was INR 5.29 compared to basic earnings per share from continuing operations of INR 0.6 a year ago. Diluted loss per share from continuing operations was INR 5.29 compared to diluted earnings per share from continuing operations of INR 0.6 a year ago.
For the nine months, sales was INR 57.33 million compared to INR 319.14 million a year ago. Revenue was INR 58.25 million compared to INR 319.15 million a year ago. Net loss was INR 22.74 million compared to net income of INR 0.517 million a year ago. Basic loss per share from continuing operations was INR 7.41 compared to basic earnings per share from continuing operations of INR 0.05 a year ago. Diluted loss per share from continuing operations was INR 7.41 compared to diluted earnings per share from continuing operations of INR 0.05 a year ago.